 Karyopharms growth strategy has generated significant increases in total revenues, net product revenue growth, licensing revenue, and milestone revenue. Despite the progress, the market continues to punish KPTI. The company is focusing on XPOVIO to maximize growth in multiple myeloma while ensuring their clinical pipeline continues to make progress. I believe Karyopharm has plenty of room to grow. 